Losmapimod
Cat. No.：YN350035
| 产品名称: | Losmapimod |
| CAS No.: | 585543-15-3 |
| Chemical Name: | 6-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide |
| Synonyms: | 洛批莫德; GSK-AHAB; GW856553X; SB856553 |
| 分子量: | 383.46 |
| 分子式: | C₂₂H₂₆FN₃O₂ |
| SMILES: | CC1=C(C2=NC=C(C(NCC(C)(C)C)=O)C=C2)C=C(C(NC3CC3)=O)C=C1F |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Losmapimod (GSK-AHAB) 是一种有效的，具有口服活性的选择性p38 MAPK抑制剂，抑制 p38α 和 p38β 的pKi值分别为 8.1 和 7.6。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Willette, R.N., Eybye, M.E., Olzinski, A.R., et al.Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular diseaseJ. Pharmacol. Exp. Ther.330(3),964-970(2009)
Triantaphyllopoulos, K., Madden, L., Rioja, I., et al.In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model: A pre-clinical studyClin. Exp. Rheumatol.28(2),176-185(2010)
